Clinical trial
A Phase II, Open-label, Dose Exposure Confirmation Study to Evaluate the Pharmacokinetics and Safety and Tolerability of Betrixaban (MK-4448) in Adult Patients With Nonvalvular Atrial Fibrillation or Atrial Flutter
NCT01229254 is registered in ClinicalTrials.gov with Portola Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II, Open-label, Dose Exposure Confirmation Study to Evaluate the Pharmacokinetics and Safety and Tolerability of Betrixaban (MK-4448) in Adult Patients With Nonvalvular Atrial Fibrillation or Atrial Flutter
- Lead sponsor
- Portola Pharmaceuticals
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- September 30, 2010
- Completion date
- April 30, 2011
- Enrollment
- 189 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.